Media
Corgentech to Present at Pacific Growth Equities Life Sciences Growth Conference and Needham & Company Fifth Annual Biotechnology and Medical Technology Conference
SOUTH SAN FRANCISCO, Calif., June 7, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Corgentech Inc. (Nasdaq: CGTK) today announced that John P. McLaughlin, the company's chief executive officer, will present at the Pacific Growth Equities Life Sciences Growth Conference on Monday, June 12, 2006 at 8:30 a.m. PDT in San Francisco; and at the Needham & Company Biotechnology and Medical Technology Conference on Wednesday, June 14, 2006 at 9:00 a.m. EDT in New York City.
To access the live webcasts or the subsequent archived recordings, log on to www.corgentech.com and go to the Investors page, and click on Webcasts. Please connect to Corgentech's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Corgentech
Corgentech is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has four drug candidates in clinical development for multiple potential indications, the most advanced of which, 3268, has completed Phase 3 clinical trials. To reflect the company's core focus on novel pain management therapies, the board of directors recently voted to change the company name to Anesiva. If approved by stockholders at the annual meeting on June 21, 2006, the name change will become effective immediately thereafter. Corgentech is based in South San Francisco, CA.
SOURCE Corgentech Inc.
Jennifer Cook Williams, Vice President, Investor Relations of Corgentech Inc., +1-650-624-9600, or [email protected]
http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
News Provided by COMTEX
